After a median 9.6 months of cabozantinib treatment, the 6-month brain metastasis progression-free rate was 56%, meeting the study’s primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback